Open-label trial of atomoxetine hydrochloride in adults with ADHD.
Artikel i vetenskaplig tidskrift, 2010
Background: While atomoxetine is an established treatment for attention-deficit/hyperactivity disorder in children, few studies have examined its efficacy for adults. Methods: Open-label trial of atomoxetine in 20 individuals with ADHD, aged 19-47 years, for 10 weeks, and a total of one year for responders. Results: Ten patients met primary efficacy criteria at 10 weeks. Only one patient completed the whole study. Six patients discontinued before 10 weeks and thirteen at 10 weeks or later, mainly because of side-effects (aggression, depressed mood, raised liver enzymes, thyroid hormones, diastolic blood pressure), decreasing efficacy or non-compliance. Conclusion: Fifty percent responded to treatment, but only one patient (5%) felt sufficient improvement to continue for one year. Dosage may have been too low, and baseline impairment too high, for atomoxetine to have sufficient effect on ADHD symptoms in our group of adults. The majority had few side-effects, but several terminated treatment because of adverse effects.
Adult
Adverse effects
Adverse effects
Drug Administration Schedule
Intention to Treat Analysis
Time
Attention Deficit Disorder with Hyperactivity
Propylamines
Administration & dosage
Treatment Outcome
Adrenergic Uptake Inhibitors
Middle Aged
Male
Longitudinal Studies
Administration & dosage
Humans
Patient Selection
Drug therapy
Female
Författare
Mats Johnson
Göteborgs universitet
Mats Cederlund
Göteborgs universitet
Maria Råstam
Göteborgs universitet
Björn Areskoug
Göteborgs universitet
Christopher Gillberg
Göteborgs universitet
Journal of Attention Disorders
1087-0547 (ISSN)
Vol. 13 5 539-545Ämneskategorier
Psykiatri
DOI
10.1177/1087054709332372
PubMed
19458384